Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
2x Long VIX Futures ETF
UVIX
5
iShares Core S&P 500 ETF
IVV
CN Stock MarketDetailed Quotes
Wuhan Easy Diagnosis Biomedicine (002932)
- 20.91
- -0.21-0.99%
Market Closed Jul 18 15:00 CST
4.86BMarket Cap125.21P/E (TTM)
21.45High20.85Low26.05KlotVolume21.20Open21.12Prev Close54.71MTurnover1.67%Turnover Ratio65.34P/E (Static)232.52MShares21.7652wk High0.88P/B3.26BFloat Cap14.1552wk Low23.23Limit Up156.09MShs Float58.49Historical High19.01Limit Down2.84%Amplitude0.20Historical Low1.23Dividend TTM21.00Avg Price14.17KlotAsk5.88%Div Yield TTM100Lot Size11.38KlotBid
Wuhan Easy Diagnosis Biomedicine (002932) News
Wuhan Easy Diagnosis Biomedicine: 2025 semi-annual results forecast
Express News | Wuhan Easy Diagnosis Biomedicine has invested in the establishment of a new company that includes the Business of bio-based materials.
Wuhan Easy Diagnosis Biomedicine (002932.SZ): The sales proportion of six respiratory virus nucleic acid detection kits is currently relatively small.
On June 12, Gelonghui reported that Wuhan Easy Diagnosis Biomedicine (002932.SZ) stated in its investor relations that the company's six respiratory virus nucleic acid testing kits (fluorescent PCR method) will obtain the Medical Devices registration certificate in May 2025 and will be officially put on sale. As of now, the sales proportion is relatively small.
Wuhan Easy Diagnosis Biomedicine (002932.SZ): Has not yet entered the vaccine or innovative drug sector of the infectious disease Industry Chain.
On June 12, Glonghui reported that Wuhan Easy Diagnosis Biomedicine (002932.SZ) stated in an investor relationship that the company has not yet entered the vaccine or innovative drug field of the infectious disease Industry Chain. The company is currently focusing on its existing core technological advantages and exploring new growth points in two ways: on one hand, increasing R&D investment in the fields of in vitro diagnostic reagents and high-end Medical Devices, promoting technological iteration and product upgrades; on the other hand, actively evaluating investment and acquisition opportunities that align with its Global Strategy, with a focus on technologies and market resources that can create synergy with its existing Business to enhance market share.
Express News | DeepSeek released the Prover-V2 model, with a parameter count reaching 671 billion.
Matilda Biotech: Report for the first quarter of 2025
Matilda Biotech: 2024 Annual Report
Matilda Biotech: 2024 Annual Report Summary
Express News | Overview of A-share Share Buyback: 15 companies disclosed their buyback progress.
Express News | Focusing on critical conditions, Wuhan Easy Diagnosis Biomedicine and Likang Biomedical have reached a Global Strategy cooperation.
Wuhan Easy Diagnosis Biomedicine (002932.SZ): The first fundraising investment project has been completed, and the remaining funds will be used for Other fundraising investment projects.
On February 13, 2023, Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that on February 13, 2025, the fourth meeting of the Board of Directors and the fifteenth meeting of the Supervisory Board of Wuhan Easy Diagnosis Biomedicine Technology Co., Ltd. were convened, where the resolution on the "Completion of Fundraising Projects from the Initial Public Offering of Stocks and Allocation of Remaining Funds to Other Fundraising Projects" was approved. The company agrees to formally conclude the fundraising projects from the initial public offering of stocks and allocate the remaining funds of 11.1108 million yuan (including financial income, deposit interest, etc., with the final amount based on the special account transfer on the day of funds being transferred.
Express News | Summary of Shareholding changes on February 10.
Express News | Wuhan Easy Diagnosis Biomedicine: Director Wang Jianfei plans to reduce the Shareholding of the company by no more than 13,113 shares.
Wuhan Easy Diagnosis Biomedicine (002932.SZ): has cumulatively repurchased 5.61% of its shares.
Gelonghui reported on February 5 that Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that as of January 31, 2025, the company repurchased 13,034,741 shares through a dedicated repurchase securities account via centralized bidding (including parts used to maintain the company's value and shareholder rights), accounting for 5.61% of the company's total share capital; the highest Fill Price for the repurchased shares was 20.98 yuan/share, the lowest Fill Price was 15.33 yuan/share, and the total transaction amount was 0.248 billion yuan (excluding transaction taxes and fees).
Wuhan Easy Diagnosis Biomedicine (002932.SZ) has cumulatively repurchased 5.05% of its shares, spending approximately 0.224 billion yuan.
Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that as of November 29, 2024, the company has cumulatively through the return...
Express News | wuhan easy diagnosis biomedicine: repurchased company shares to reach 5% ratio.
Express News | Hubei Minghuikang Biotechnology Co., Ltd. is established, and Wuhan Easy Diagnosis Biomedicine holds an indirect wholly-owned stake.
Express News | Wuhan Easy Diagnosis Biomedicine Investment Established a New Technology Company Including AI-related Business
Matilda Biotech: Report for the third quarter of 2024
wuhan easy diagnosis biomedicine (002932.SZ) released its performance for the first three quarters, with a net income of 80.9384 million yuan, a year-on-year decrease of 44.30%.
Wuhan Easy Diagnosis Biomedicine (002932.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Market Insights
Tariff Storm Hits: Hedge with ETFs? Tariff Storm Hits: Hedge with ETFs?
The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios. The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios.
Unlock Now
Discussing
Focus on tariff dynamics! How to plan most securely in the near future?
Recently, Trump's tariffs have sparked controversy again. Trump stated that the United States would impose a 100% tariff on Russia, a 30% ta
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"